Two of the most promising treatments for obesity in recent years are semaglutide, a GLP-1 agonist, and tirzepatide, a dual GLP-1/GIP agonist. These peptides have garnered attention for their impressive efficacy in weight loss and metabolic improvement, but they differ in their mechanisms, dosing, side effects, and outcomes. In this podcast, we’ll explore how these […]